File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine
  • Basic View
  • Metadata View
  • XML View
TitleSeroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine
 
AuthorsZhou, Y2
Ng, DMW2
Seto, WH1
Ip, DKM2
Kwok, HKH1
Ma, ESK2
Ng, S2
Lau, LLH2
Peiris, JSM2 3
Cowling, BJ2
 
KeywordsInfluenza virus A H1N1
Seroprevalence
2009 H1N1 influenza
Antibody titer
Immunogenicity
 
Issue Date2011
 
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
 
CitationPlos One, 2011, v. 6 n. 11 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0027169
 
AbstractBackground: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local healthcare workers had received the vaccine by February 2010. Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine (Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination inhibition (HI) and viral neutralization (VN) assays. Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval (CI): 44%-63%) had antibody titer ≥1:40 by HI and 42% (95% CI: 33%-52%) had antibody titer ≥1:40 by VN. The proportion of HCWs with antibody titer ≥1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer ≥1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007-08 seasonal influenza vaccine (odds ratio: 0.43; 95% CI: 0.19-1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not statistically significant. Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in HCWs. © 2011 Zhou et al.
 
ISSN1932-6203
2013 Impact Factor: 3.534
2013 SCImago Journal Rankings: 1.724
 
DOIhttp://dx.doi.org/10.1371/journal.pone.0027169
 
PubMed Central IDPMC3213124
 
ISI Accession Number IDWOS:000297348800017
Funding AgencyGrant Number
Hong Kong University Grants CommitteeAoE/M-12/06
MedImmune Inc.
Roche
Funding Information:

This work has received financial support from the Area of Excellence Scheme of the Hong Kong University Grants Committee (grant no. AoE/M-12/06). The funding body was not involved in the collection, analysis, and interpretation of data, the writing of the article, or the decision to submit it for publication.

 
ReferencesReferences in Scopus
 
GrantsControl of Pandemic and Inter-pandemic Influenza
 
DC FieldValue
dc.contributor.authorZhou, Y
 
dc.contributor.authorNg, DMW
 
dc.contributor.authorSeto, WH
 
dc.contributor.authorIp, DKM
 
dc.contributor.authorKwok, HKH
 
dc.contributor.authorMa, ESK
 
dc.contributor.authorNg, S
 
dc.contributor.authorLau, LLH
 
dc.contributor.authorPeiris, JSM
 
dc.contributor.authorCowling, BJ
 
dc.date.accessioned2011-12-21T08:54:26Z
 
dc.date.available2011-12-21T08:54:26Z
 
dc.date.issued2011
 
dc.description.abstractBackground: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local healthcare workers had received the vaccine by February 2010. Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine (Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination inhibition (HI) and viral neutralization (VN) assays. Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval (CI): 44%-63%) had antibody titer ≥1:40 by HI and 42% (95% CI: 33%-52%) had antibody titer ≥1:40 by VN. The proportion of HCWs with antibody titer ≥1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer ≥1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007-08 seasonal influenza vaccine (odds ratio: 0.43; 95% CI: 0.19-1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not statistically significant. Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in HCWs. © 2011 Zhou et al.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationPlos One, 2011, v. 6 n. 11 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0027169
 
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0027169
 
dc.identifier.epagee27169
 
dc.identifier.hkuros197999
 
dc.identifier.isiWOS:000297348800017
Funding AgencyGrant Number
Hong Kong University Grants CommitteeAoE/M-12/06
MedImmune Inc.
Roche
Funding Information:

This work has received financial support from the Area of Excellence Scheme of the Hong Kong University Grants Committee (grant no. AoE/M-12/06). The funding body was not involved in the collection, analysis, and interpretation of data, the writing of the article, or the decision to submit it for publication.

 
dc.identifier.issn1932-6203
2013 Impact Factor: 3.534
2013 SCImago Journal Rankings: 1.724
 
dc.identifier.issue11
 
dc.identifier.pmcidPMC3213124
 
dc.identifier.pmid22102878
 
dc.identifier.scopuseid_2-s2.0-80755159561
 
dc.identifier.spagee27169
 
dc.identifier.urihttp://hdl.handle.net/10722/143772
 
dc.identifier.volume6
 
dc.languageeng
 
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
 
dc.publisher.placeUnited States
 
dc.relation.ispartofPLoS ONE
 
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subjectInfluenza virus A H1N1
 
dc.subjectSeroprevalence
 
dc.subject2009 H1N1 influenza
 
dc.subjectAntibody titer
 
dc.subjectImmunogenicity
 
dc.titleSeroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhou, Y</contributor.author>
<contributor.author>Ng, DMW</contributor.author>
<contributor.author>Seto, WH</contributor.author>
<contributor.author>Ip, DKM</contributor.author>
<contributor.author>Kwok, HKH</contributor.author>
<contributor.author>Ma, ESK</contributor.author>
<contributor.author>Ng, S</contributor.author>
<contributor.author>Lau, LLH</contributor.author>
<contributor.author>Peiris, JSM</contributor.author>
<contributor.author>Cowling, BJ</contributor.author>
<date.accessioned>2011-12-21T08:54:26Z</date.accessioned>
<date.available>2011-12-21T08:54:26Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Plos One, 2011, v. 6 n. 11</identifier.citation>
<identifier.issn>1932-6203</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/143772</identifier.uri>
<description.abstract>Background: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local healthcare workers had received the vaccine by February 2010. Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine (Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination inhibition (HI) and viral neutralization (VN) assays. Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval (CI): 44%-63%) had antibody titer &#8805;1:40 by HI and 42% (95% CI: 33%-52%) had antibody titer &#8805;1:40 by VN. The proportion of HCWs with antibody titer &#8805;1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer &#8805;1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007-08 seasonal influenza vaccine (odds ratio: 0.43; 95% CI: 0.19-1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not statistically significant. Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in HCWs. &#169; 2011 Zhou et al.</description.abstract>
<language>eng</language>
<publisher>Public Library of Science. The Journal&apos;s web site is located at http://www.plosone.org/home.action</publisher>
<relation.ispartof>PLoS ONE</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>Influenza virus A H1N1</subject>
<subject>Seroprevalence</subject>
<subject>2009 H1N1 influenza</subject>
<subject>Antibody titer</subject>
<subject>Immunogenicity</subject>
<title>Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1371/journal.pone.0027169</identifier.doi>
<identifier.pmid>22102878</identifier.pmid>
<identifier.pmcid>PMC3213124</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-80755159561</identifier.scopus>
<identifier.hkuros>197999</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80755159561&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>6</identifier.volume>
<identifier.issue>11</identifier.issue>
<identifier.spage>e27169</identifier.spage>
<identifier.epage>e27169</identifier.epage>
<identifier.isi>WOS:000297348800017</identifier.isi>
<publisher.place>United States</publisher.place>
<relation.project>Control of Pandemic and Inter-pandemic Influenza</relation.project>
<bitstream.url>http://hub.hku.hk/bitstream/10722/143772/1/pone.0027169.pdf</bitstream.url>
</item>
Author Affiliations
  1. Hong Kong Hospital Authority
  2. The University of Hong Kong
  3. HKU-Pasteur Research Centre